furosemide	Warfarin	17	19	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		4603	11289	4603	D014859
furosemide	Warfarin	17	19	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		4603	11289	4603	D014859
furosemide	Warfarin	16	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	11289	4603	D014859
furosemide	Warfarin	16	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	11289	4603	D014859
furosemide	Warfarin	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		4603	11289	4603	D014859
furosemide	Warfarin	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		4603	11289	4603	D014859
furosemide	aliskiren	17	15	true	positive	7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  		4603	325646	4603	325646
furosemide	aliskiren	17	15	true	positive	7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  		4603	325646	4603	325646
furosemide	aliskiren	17	17	true	positive	Patients receiving furosemide could find its effect diminished after starting aliskiren.  		4603	325646	4603	325646
furosemide	aliskiren	17	17	true	positive	Patients receiving furosemide could find its effect diminished after starting aliskiren.  		4603	325646	4603	325646
furosemide	aliskiren	17	16	true	positive	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  		4603	325646	4603	325646
furosemide	aliskiren	17	16	true	positive	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  		4603	325646	4603	325646
furosemide	aliskiren	17	19	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		4603	325646	4603	325646
furosemide	aliskiren	17	19	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		4603	325646	4603	325646
furosemide	aliskiren	17	18	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	325646	4603	325646
furosemide	aliskiren	17	18	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	325646	4603	325646
furosemide	aliskiren	16	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	325646	4603	325646
furosemide	aliskiren	16	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	325646	4603	325646
furosemide	aliskiren	16	15	true	positive	7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	325646	4603	325646
furosemide	aliskiren	16	15	true	positive	7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	325646	4603	325646
furosemide	aliskiren	16	17	true	positive	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  		4603	325646	4603	325646
furosemide	aliskiren	16	17	true	positive	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  		4603	325646	4603	325646
furosemide	aliskiren	16	16	true	positive	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	325646	4603	325646
furosemide	aliskiren	16	16	true	positive	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	325646	4603	325646
furosemide	aliskiren	16	18	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	325646	4603	325646
furosemide	aliskiren	16	18	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	325646	4603	325646
furosemide	aliskiren	14	12	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		4603	325646	4603	325646
furosemide	aliskiren	14	12	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		4603	325646	4603	325646
furosemide	aliskiren	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		4603	325646	4603	325646
furosemide	aliskiren	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		4603	325646	4603	325646
furosemide	aliskiren	14	15	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		4603	325646	4603	325646
furosemide	aliskiren	14	15	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		4603	325646	4603	325646
furosemide	aliskiren	14	16	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	325646	4603	325646
furosemide	aliskiren	14	16	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	325646	4603	325646
furosemide	atorvastatin	17	18	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	83367	4603	C065179
furosemide	atorvastatin	17	18	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	83367	4603	C065179
furosemide	atorvastatin	16	18	false	none	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	83367	4603	C065179
furosemide	atorvastatin	16	18	false	none	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	83367	4603	C065179
furosemide	Verapamil	14	12	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		4603	11170	4603	11170
furosemide	Verapamil	14	12	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		4603	11170	4603	11170
furosemide	warfarin	17	19	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		4603	11289	4603	D014859
furosemide	warfarin	17	19	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		4603	11289	4603	D014859
furosemide	warfarin	16	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	11289	4603	D014859
furosemide	warfarin	16	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	11289	4603	D014859
furosemide	warfarin	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		4603	11289	4603	D014859
furosemide	warfarin	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		4603	11289	4603	D014859
furosemide	digoxin	17	18	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	3407	4603	3407
furosemide	digoxin	17	18	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	3407	4603	3407
furosemide	digoxin	16	18	false	none	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	3407	4603	3407
furosemide	digoxin	16	18	false	none	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	3407	4603	3407
furosemide	digoxin	16	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	3407	4603	3407
furosemide	digoxin	16	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	3407	4603	3407
furosemide	digoxin	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		4603	3407	4603	3407
furosemide	digoxin	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		4603	3407	4603	3407
furosemide	atenolol	17	18	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	1202	4603	D001262
furosemide	atenolol	17	18	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	1202	4603	D001262
furosemide	atenolol	16	18	false	none	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	1202	4603	D001262
furosemide	atenolol	16	18	false	none	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	1202	4603	D001262
furosemide	atenolol	16	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	1202	4603	D001262
furosemide	atenolol	16	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	1202	4603	D001262
furosemide	atenolol	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		4603	1202	4603	D001262
furosemide	atenolol	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		4603	1202	4603	D001262
furosemide	metformin	17	18	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	6809	4603	6809
furosemide	metformin	17	18	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	6809	4603	6809
furosemide	metformin	16	18	false	none	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	6809	4603	6809
furosemide	metformin	16	18	false	none	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	6809	4603	6809
furosemide	metformin	16	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	6809	4603	6809
furosemide	metformin	16	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	6809	4603	6809
furosemide	metformin	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		4603	6809	4603	6809
furosemide	metformin	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		4603	6809	4603	6809
furosemide	verapamil	14	12	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		4603	11170	4603	11170
furosemide	verapamil	14	12	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		4603	11170	4603	11170
furosemide	ramipril	17	18	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	35296	4603	D017257
furosemide	ramipril	17	18	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	35296	4603	D017257
furosemide	ramipril	16	18	false	none	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	35296	4603	D017257
furosemide	ramipril	16	18	false	none	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	35296	4603	D017257
furosemide	ramipril	16	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	35296	4603	D017257
furosemide	ramipril	16	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	35296	4603	D017257
furosemide	ramipril	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		4603	35296	4603	D017257
furosemide	ramipril	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		4603	35296	4603	D017257
furosemide	amlodipine	17	18	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	17767	4603	D017311
furosemide	amlodipine	17	18	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	17767	4603	D017311
furosemide	amlodipine	16	18	false	none	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	17767	4603	D017311
furosemide	amlodipine	16	18	false	none	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	17767	4603	D017311
furosemide	amlodipine	16	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	17767	4603	D017311
furosemide	amlodipine	16	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	17767	4603	D017311
furosemide	amlodipine	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		4603	17767	4603	D017311
furosemide	amlodipine	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		4603	17767	4603	D017311
furosemide	lovastatin	17	18	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	6472	4603	6472
furosemide	lovastatin	17	18	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	6472	4603	6472
furosemide	lovastatin	16	18	false	none	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	6472	4603	6472
furosemide	lovastatin	16	18	false	none	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	6472	4603	6472
furosemide	lovastatin	16	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	6472	4603	6472
furosemide	lovastatin	16	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	6472	4603	6472
furosemide	lovastatin	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		4603	6472	4603	6472
furosemide	lovastatin	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		4603	6472	4603	6472
furosemide	celecoxib	17	18	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	140587	4603	C105934
furosemide	celecoxib	17	18	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	140587	4603	C105934
furosemide	celecoxib	16	18	false	none	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	140587	4603	C105934
furosemide	celecoxib	16	18	false	none	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	140587	4603	C105934
furosemide	celecoxib	16	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	140587	4603	C105934
furosemide	celecoxib	16	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	140587	4603	C105934
furosemide	celecoxib	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		4603	140587	4603	C105934
furosemide	celecoxib	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		4603	140587	4603	C105934
furosemide	Aliskiren	17	15	true	positive	7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  		4603	325646	4603	325646
furosemide	Aliskiren	17	15	true	positive	7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  		4603	325646	4603	325646
furosemide	Aliskiren	17	17	true	positive	Patients receiving furosemide could find its effect diminished after starting aliskiren.  		4603	325646	4603	325646
furosemide	Aliskiren	17	17	true	positive	Patients receiving furosemide could find its effect diminished after starting aliskiren.  		4603	325646	4603	325646
furosemide	Aliskiren	17	16	true	positive	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  		4603	325646	4603	325646
furosemide	Aliskiren	17	16	true	positive	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  		4603	325646	4603	325646
furosemide	Aliskiren	17	19	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		4603	325646	4603	325646
furosemide	Aliskiren	17	19	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		4603	325646	4603	325646
furosemide	Aliskiren	17	18	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	325646	4603	325646
furosemide	Aliskiren	17	18	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	325646	4603	325646
furosemide	Aliskiren	16	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	325646	4603	325646
furosemide	Aliskiren	16	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	325646	4603	325646
furosemide	Aliskiren	16	15	true	positive	7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	325646	4603	325646
furosemide	Aliskiren	16	15	true	positive	7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	325646	4603	325646
furosemide	Aliskiren	16	17	true	positive	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  		4603	325646	4603	325646
furosemide	Aliskiren	16	17	true	positive	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  		4603	325646	4603	325646
furosemide	Aliskiren	16	16	true	positive	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	325646	4603	325646
furosemide	Aliskiren	16	16	true	positive	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	325646	4603	325646
furosemide	Aliskiren	16	18	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	325646	4603	325646
furosemide	Aliskiren	16	18	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	325646	4603	325646
furosemide	Aliskiren	14	12	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		4603	325646	4603	325646
furosemide	Aliskiren	14	12	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		4603	325646	4603	325646
furosemide	Aliskiren	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		4603	325646	4603	325646
furosemide	Aliskiren	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		4603	325646	4603	325646
furosemide	Aliskiren	14	15	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		4603	325646	4603	325646
furosemide	Aliskiren	14	15	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		4603	325646	4603	325646
furosemide	Aliskiren	14	16	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	325646	4603	325646
furosemide	Aliskiren	14	16	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	325646	4603	325646
furosemide	hydrochlorothiazide	17	18	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	5487	4603	D006852
furosemide	hydrochlorothiazide	17	18	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	5487	4603	D006852
furosemide	hydrochlorothiazide	16	18	false	none	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	5487	4603	D006852
furosemide	hydrochlorothiazide	16	18	false	none	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	5487	4603	D006852
furosemide	hydrochlorothiazide	16	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	5487	4603	D006852
furosemide	hydrochlorothiazide	16	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	5487	4603	D006852
furosemide	hydrochlorothiazide	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		4603	5487	4603	D006852
furosemide	hydrochlorothiazide	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		4603	5487	4603	D006852
furosemide	Atorvastatin	17	18	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	83367	4603	C065179
furosemide	Atorvastatin	17	18	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	83367	4603	C065179
furosemide	Atorvastatin	16	18	false	none	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	83367	4603	C065179
furosemide	Atorvastatin	16	18	false	none	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	83367	4603	C065179
Warfarin	aliskiren	19	17	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	325646	D014859	325646
Warfarin	aliskiren	19	17	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	325646	D014859	325646
Warfarin	aliskiren	19	19	true	negative	Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	325646	D014859	325646
Warfarin	aliskiren	19	19	true	negative	Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	325646	D014859	325646
Warfarin	aliskiren	19	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	325646	D014859	325646
Warfarin	aliskiren	19	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	325646	D014859	325646
Warfarin	aliskiren	14	12	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	325646	D014859	325646
Warfarin	aliskiren	14	12	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	325646	D014859	325646
Warfarin	aliskiren	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	325646	D014859	325646
Warfarin	aliskiren	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	325646	D014859	325646
Warfarin	aliskiren	14	15	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		11289	325646	D014859	325646
Warfarin	aliskiren	14	15	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		11289	325646	D014859	325646
Warfarin	aliskiren	14	16	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		11289	325646	D014859	325646
Warfarin	aliskiren	14	16	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		11289	325646	D014859	325646
Warfarin	atorvastatin	19	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	83367	D014859	C065179
Warfarin	atorvastatin	19	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	83367	D014859	C065179
Warfarin	Verapamil	14	12	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	11170	D014859	11170
Warfarin	Verapamil	14	12	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	11170	D014859	11170
Warfarin	digoxin	19	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	3407	D014859	3407
Warfarin	digoxin	19	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	3407	D014859	3407
Warfarin	digoxin	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	3407	D014859	3407
Warfarin	digoxin	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	3407	D014859	3407
Warfarin	atenolol	19	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	1202	D014859	D001262
Warfarin	atenolol	19	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	1202	D014859	D001262
Warfarin	atenolol	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	1202	D014859	D001262
Warfarin	atenolol	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	1202	D014859	D001262
Warfarin	metformin	19	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	6809	D014859	6809
Warfarin	metformin	19	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	6809	D014859	6809
Warfarin	metformin	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	6809	D014859	6809
Warfarin	metformin	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	6809	D014859	6809
Warfarin	verapamil	14	12	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	11170	D014859	11170
Warfarin	verapamil	14	12	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	11170	D014859	11170
Warfarin	ramipril	19	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	35296	D014859	D017257
Warfarin	ramipril	19	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	35296	D014859	D017257
Warfarin	ramipril	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	35296	D014859	D017257
Warfarin	ramipril	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	35296	D014859	D017257
Warfarin	amlodipine	19	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	17767	D014859	D017311
Warfarin	amlodipine	19	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	17767	D014859	D017311
Warfarin	amlodipine	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	17767	D014859	D017311
Warfarin	amlodipine	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	17767	D014859	D017311
Warfarin	lovastatin	19	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	6472	D014859	6472
Warfarin	lovastatin	19	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	6472	D014859	6472
Warfarin	lovastatin	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	6472	D014859	6472
Warfarin	lovastatin	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	6472	D014859	6472
Warfarin	celecoxib	19	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	140587	D014859	C105934
Warfarin	celecoxib	19	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	140587	D014859	C105934
Warfarin	celecoxib	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	140587	D014859	C105934
Warfarin	celecoxib	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	140587	D014859	C105934
Warfarin	Furosemide	19	17	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	4603	D014859	4603
Warfarin	Furosemide	19	17	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	4603	D014859	4603
Warfarin	Furosemide	14	16	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		11289	4603	D014859	4603
Warfarin	Furosemide	14	16	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		11289	4603	D014859	4603
Warfarin	Furosemide	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	4603	D014859	4603
Warfarin	Furosemide	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	4603	D014859	4603
Warfarin	Aliskiren	19	17	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	325646	D014859	325646
Warfarin	Aliskiren	19	17	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	325646	D014859	325646
Warfarin	Aliskiren	19	19	true	negative	Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	325646	D014859	325646
Warfarin	Aliskiren	19	19	true	negative	Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	325646	D014859	325646
Warfarin	Aliskiren	19	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	325646	D014859	325646
Warfarin	Aliskiren	19	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	325646	D014859	325646
Warfarin	Aliskiren	14	12	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	325646	D014859	325646
Warfarin	Aliskiren	14	12	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	325646	D014859	325646
Warfarin	Aliskiren	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	325646	D014859	325646
Warfarin	Aliskiren	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	325646	D014859	325646
Warfarin	Aliskiren	14	15	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		11289	325646	D014859	325646
Warfarin	Aliskiren	14	15	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		11289	325646	D014859	325646
Warfarin	Aliskiren	14	16	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		11289	325646	D014859	325646
Warfarin	Aliskiren	14	16	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		11289	325646	D014859	325646
Warfarin	hydrochlorothiazide	19	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	5487	D014859	D006852
Warfarin	hydrochlorothiazide	19	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	5487	D014859	D006852
Warfarin	hydrochlorothiazide	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	5487	D014859	D006852
Warfarin	hydrochlorothiazide	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	5487	D014859	D006852
Warfarin	Atorvastatin	19	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	83367	D014859	C065179
Warfarin	Atorvastatin	19	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	83367	D014859	C065179
aliskiren	Ketoconazole	5	6	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  		325646	6135	325646	D007654
aliskiren	Ketoconazole	5	6	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  		325646	6135	325646	D007654
aliskiren	Ketoconazole	6	6	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  		325646	6135	325646	D007654
aliskiren	Ketoconazole	6	6	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  		325646	6135	325646	D007654
aliskiren	Ketoconazole	7	6	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  		325646	6135	325646	D007654
aliskiren	Ketoconazole	7	6	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  		325646	6135	325646	D007654
aliskiren	Ketoconazole	8	6	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  		325646	6135	325646	D007654
aliskiren	Ketoconazole	8	6	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  		325646	6135	325646	D007654
aliskiren	irbesartan	1	2	false	none	7  DRUG INTERACTIONS    7.1 Effects of Other Drugs on Aliskiren    Based on in vitro studies, aliskiren is metabolized by CYP 3A4.  Irbesartan: Coadministration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.  		325646	83818	325646	83818
aliskiren	irbesartan	1	2	false	none	7  DRUG INTERACTIONS    7.1 Effects of Other Drugs on Aliskiren    Based on in vitro studies, aliskiren is metabolized by CYP 3A4.  Irbesartan: Coadministration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.  		325646	83818	325646	83818
aliskiren	irbesartan	2	2	true	positive	Irbesartan: Coadministration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.  		325646	83818	325646	83818
aliskiren	irbesartan	2	2	true	positive	Irbesartan: Coadministration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.  		325646	83818	325646	83818
aliskiren	irbesartan	3	2	true	positive	Irbesartan: Coadministration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.  P-glycoprotein Effects: Pgp (MDR1/Mdr1a/1b) was found to be the major efflux system involved in absorption and disposition of aliskiren in preclinical studies.  		325646	83818	325646	83818
aliskiren	irbesartan	3	2	true	positive	Irbesartan: Coadministration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.  P-glycoprotein Effects: Pgp (MDR1/Mdr1a/1b) was found to be the major efflux system involved in absorption and disposition of aliskiren in preclinical studies.  		325646	83818	325646	83818
aliskiren	atorvastatin	3	5	false	none	P-glycoprotein Effects: Pgp (MDR1/Mdr1a/1b) was found to be the major efflux system involved in absorption and disposition of aliskiren in preclinical studies.  The potential for drug interactions at the Pgp site will likely depend on the degree of inhibition of this transporter.  Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  		325646	83367	325646	C065179
aliskiren	atorvastatin	3	5	false	none	P-glycoprotein Effects: Pgp (MDR1/Mdr1a/1b) was found to be the major efflux system involved in absorption and disposition of aliskiren in preclinical studies.  The potential for drug interactions at the Pgp site will likely depend on the degree of inhibition of this transporter.  Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  		325646	83367	325646	C065179
aliskiren	atorvastatin	5	5	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  		325646	83367	325646	C065179
aliskiren	atorvastatin	5	5	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  		325646	83367	325646	C065179
aliskiren	atorvastatin	6	5	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  		325646	83367	325646	C065179
aliskiren	atorvastatin	6	5	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  		325646	83367	325646	C065179
aliskiren	atorvastatin	7	5	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  		325646	83367	325646	C065179
aliskiren	atorvastatin	7	5	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  		325646	83367	325646	C065179
aliskiren	atorvastatin	17	18	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	83367	325646	C065179
aliskiren	atorvastatin	17	18	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	83367	325646	C065179
aliskiren	atorvastatin	16	18	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	83367	325646	C065179
aliskiren	atorvastatin	16	18	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	83367	325646	C065179
aliskiren	atorvastatin	19	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		325646	83367	325646	C065179
aliskiren	atorvastatin	19	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		325646	83367	325646	C065179
aliskiren	atorvastatin	18	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	83367	325646	C065179
aliskiren	atorvastatin	18	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	83367	325646	C065179
aliskiren	Itraconazole	6	8	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  		325646	28031	325646	D017964
aliskiren	Itraconazole	6	8	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  		325646	28031	325646	D017964
aliskiren	Itraconazole	7	8	true	positive	A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  		325646	28031	325646	D017964
aliskiren	Itraconazole	7	8	true	positive	A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  		325646	28031	325646	D017964
aliskiren	Itraconazole	7	9	true	positive	A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  		325646	28031	325646	D017964
aliskiren	Itraconazole	7	9	true	positive	A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  		325646	28031	325646	D017964
aliskiren	Itraconazole	8	8	true	positive	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  		325646	28031	325646	D017964
aliskiren	Itraconazole	8	8	true	positive	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  		325646	28031	325646	D017964
aliskiren	Itraconazole	8	9	false	none	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  		325646	28031	325646	D017964
aliskiren	Itraconazole	8	9	false	none	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  		325646	28031	325646	D017964
aliskiren	Itraconazole	9	8	false	none	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  		325646	28031	325646	D017964
aliskiren	Itraconazole	9	8	false	none	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  		325646	28031	325646	D017964
aliskiren	Itraconazole	9	9	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  		325646	28031	325646	D017964
aliskiren	Itraconazole	9	9	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  		325646	28031	325646	D017964
aliskiren	Itraconazole	10	8	false	none	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		325646	28031	325646	D017964
aliskiren	Itraconazole	10	8	false	none	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		325646	28031	325646	D017964
aliskiren	Itraconazole	10	9	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		325646	28031	325646	D017964
aliskiren	Itraconazole	10	9	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		325646	28031	325646	D017964
aliskiren	Itraconazole	11	9	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  		325646	28031	325646	D017964
aliskiren	Itraconazole	11	9	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  		325646	28031	325646	D017964
aliskiren	Verapamil	10	12	false	none	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		325646	11170	325646	11170
aliskiren	Verapamil	10	12	false	none	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		325646	11170	325646	11170
aliskiren	Verapamil	11	12	false	none	Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		325646	11170	325646	11170
aliskiren	Verapamil	11	12	false	none	Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		325646	11170	325646	11170
aliskiren	Verapamil	12	12	true	positive	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		325646	11170	325646	11170
aliskiren	Verapamil	12	12	true	positive	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		325646	11170	325646	11170
aliskiren	Verapamil	14	12	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	11170	325646	11170
aliskiren	Verapamil	14	12	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	11170	325646	11170
aliskiren	warfarin	12	14	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	11289	325646	D014859
aliskiren	warfarin	12	14	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	11289	325646	D014859
aliskiren	warfarin	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	11289	325646	D014859
aliskiren	warfarin	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	11289	325646	D014859
aliskiren	warfarin	15	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		325646	11289	325646	D014859
aliskiren	warfarin	15	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		325646	11289	325646	D014859
aliskiren	warfarin	17	19	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		325646	11289	325646	D014859
aliskiren	warfarin	17	19	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		325646	11289	325646	D014859
aliskiren	warfarin	16	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		325646	11289	325646	D014859
aliskiren	warfarin	16	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		325646	11289	325646	D014859
aliskiren	warfarin	19	19	true	negative	Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		325646	11289	325646	D014859
aliskiren	warfarin	19	19	true	negative	Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		325646	11289	325646	D014859
aliskiren	warfarin	18	19	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		325646	11289	325646	D014859
aliskiren	warfarin	18	19	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		325646	11289	325646	D014859
aliskiren	digoxin	12	14	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	3407	325646	3407
aliskiren	digoxin	12	14	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	3407	325646	3407
aliskiren	digoxin	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	3407	325646	3407
aliskiren	digoxin	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	3407	325646	3407
aliskiren	digoxin	15	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		325646	3407	325646	3407
aliskiren	digoxin	15	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		325646	3407	325646	3407
aliskiren	digoxin	17	18	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	3407	325646	3407
aliskiren	digoxin	17	18	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	3407	325646	3407
aliskiren	digoxin	16	18	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	3407	325646	3407
aliskiren	digoxin	16	18	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	3407	325646	3407
aliskiren	digoxin	16	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		325646	3407	325646	3407
aliskiren	digoxin	16	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		325646	3407	325646	3407
aliskiren	digoxin	19	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		325646	3407	325646	3407
aliskiren	digoxin	19	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		325646	3407	325646	3407
aliskiren	digoxin	18	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	3407	325646	3407
aliskiren	digoxin	18	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	3407	325646	3407
aliskiren	atenolol	12	14	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	1202	325646	D001262
aliskiren	atenolol	12	14	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	1202	325646	D001262
aliskiren	atenolol	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	1202	325646	D001262
aliskiren	atenolol	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	1202	325646	D001262
aliskiren	atenolol	15	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		325646	1202	325646	D001262
aliskiren	atenolol	15	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		325646	1202	325646	D001262
aliskiren	atenolol	17	18	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	1202	325646	D001262
aliskiren	atenolol	17	18	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	1202	325646	D001262
aliskiren	atenolol	16	18	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	1202	325646	D001262
aliskiren	atenolol	16	18	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	1202	325646	D001262
aliskiren	atenolol	16	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		325646	1202	325646	D001262
aliskiren	atenolol	16	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		325646	1202	325646	D001262
aliskiren	atenolol	19	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		325646	1202	325646	D001262
aliskiren	atenolol	19	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		325646	1202	325646	D001262
aliskiren	atenolol	18	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	1202	325646	D001262
aliskiren	atenolol	18	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	1202	325646	D001262
aliskiren	itraconazole	6	8	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  		325646	28031	325646	D017964
aliskiren	itraconazole	6	8	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  		325646	28031	325646	D017964
aliskiren	itraconazole	7	8	true	positive	A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  		325646	28031	325646	D017964
aliskiren	itraconazole	7	8	true	positive	A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  		325646	28031	325646	D017964
aliskiren	itraconazole	7	9	true	positive	A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  		325646	28031	325646	D017964
aliskiren	itraconazole	7	9	true	positive	A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  		325646	28031	325646	D017964
aliskiren	itraconazole	8	8	true	positive	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  		325646	28031	325646	D017964
aliskiren	itraconazole	8	8	true	positive	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  		325646	28031	325646	D017964
aliskiren	itraconazole	8	9	false	none	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  		325646	28031	325646	D017964
aliskiren	itraconazole	8	9	false	none	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  		325646	28031	325646	D017964
aliskiren	itraconazole	9	8	false	none	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  		325646	28031	325646	D017964
aliskiren	itraconazole	9	8	false	none	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  		325646	28031	325646	D017964
aliskiren	itraconazole	9	9	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  		325646	28031	325646	D017964
aliskiren	itraconazole	9	9	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  		325646	28031	325646	D017964
aliskiren	itraconazole	10	8	false	none	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		325646	28031	325646	D017964
aliskiren	itraconazole	10	8	false	none	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		325646	28031	325646	D017964
aliskiren	itraconazole	10	9	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		325646	28031	325646	D017964
aliskiren	itraconazole	10	9	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		325646	28031	325646	D017964
aliskiren	itraconazole	11	9	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  		325646	28031	325646	D017964
aliskiren	itraconazole	11	9	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  		325646	28031	325646	D017964
aliskiren	metformin	12	14	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	6809	325646	6809
aliskiren	metformin	12	14	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	6809	325646	6809
aliskiren	metformin	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	6809	325646	6809
aliskiren	metformin	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	6809	325646	6809
aliskiren	metformin	15	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		325646	6809	325646	6809
aliskiren	metformin	15	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		325646	6809	325646	6809
aliskiren	metformin	17	18	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	6809	325646	6809
aliskiren	metformin	17	18	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	6809	325646	6809
aliskiren	metformin	16	18	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	6809	325646	6809
aliskiren	metformin	16	18	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	6809	325646	6809
aliskiren	metformin	16	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		325646	6809	325646	6809
aliskiren	metformin	16	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		325646	6809	325646	6809
aliskiren	metformin	19	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		325646	6809	325646	6809
aliskiren	metformin	19	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		325646	6809	325646	6809
aliskiren	metformin	18	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	6809	325646	6809
aliskiren	metformin	18	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	6809	325646	6809
aliskiren	ketoconazole	5	6	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  		325646	6135	325646	D007654
aliskiren	ketoconazole	5	6	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  		325646	6135	325646	D007654
aliskiren	ketoconazole	6	6	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  		325646	6135	325646	D007654
aliskiren	ketoconazole	6	6	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  		325646	6135	325646	D007654
aliskiren	ketoconazole	7	6	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  		325646	6135	325646	D007654
aliskiren	ketoconazole	7	6	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  		325646	6135	325646	D007654
aliskiren	ketoconazole	8	6	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  		325646	6135	325646	D007654
aliskiren	ketoconazole	8	6	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  		325646	6135	325646	D007654
aliskiren	verapamil	10	12	false	none	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		325646	11170	325646	11170
aliskiren	verapamil	10	12	false	none	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		325646	11170	325646	11170
aliskiren	verapamil	11	12	false	none	Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		325646	11170	325646	11170
aliskiren	verapamil	11	12	false	none	Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		325646	11170	325646	11170
aliskiren	verapamil	12	12	true	positive	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		325646	11170	325646	11170
aliskiren	verapamil	12	12	true	positive	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		325646	11170	325646	11170
aliskiren	verapamil	14	12	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	11170	325646	11170
aliskiren	verapamil	14	12	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	11170	325646	11170
aliskiren	ramipril	12	14	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	35296	325646	D017257
aliskiren	ramipril	12	14	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	35296	325646	D017257
aliskiren	ramipril	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	35296	325646	D017257
aliskiren	ramipril	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	35296	325646	D017257
aliskiren	ramipril	15	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		325646	35296	325646	D017257
aliskiren	ramipril	15	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		325646	35296	325646	D017257
aliskiren	ramipril	17	18	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	35296	325646	D017257
aliskiren	ramipril	17	18	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	35296	325646	D017257
aliskiren	ramipril	16	18	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	35296	325646	D017257
aliskiren	ramipril	16	18	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	35296	325646	D017257
aliskiren	ramipril	16	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		325646	35296	325646	D017257
aliskiren	ramipril	16	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		325646	35296	325646	D017257
aliskiren	ramipril	19	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		325646	35296	325646	D017257
aliskiren	ramipril	19	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		325646	35296	325646	D017257
aliskiren	ramipril	18	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	35296	325646	D017257
aliskiren	ramipril	18	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	35296	325646	D017257
aliskiren	Cyclosporine	8	10	false	none	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		325646	3008	325646	D016572
aliskiren	Cyclosporine	8	10	false	none	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		325646	3008	325646	D016572
aliskiren	Cyclosporine	9	10	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		325646	3008	325646	D016572
aliskiren	Cyclosporine	9	10	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		325646	3008	325646	D016572
aliskiren	Cyclosporine	9	11	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  		325646	3008	325646	D016572
aliskiren	Cyclosporine	9	11	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  		325646	3008	325646	D016572
aliskiren	Cyclosporine	10	10	true	positive	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		325646	3008	325646	D016572
aliskiren	Cyclosporine	10	10	true	positive	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		325646	3008	325646	D016572
aliskiren	Cyclosporine	10	11	false	none	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  		325646	3008	325646	D016572
aliskiren	Cyclosporine	10	11	false	none	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  		325646	3008	325646	D016572
aliskiren	Cyclosporine	11	10	false	none	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  		325646	3008	325646	D016572
aliskiren	Cyclosporine	11	10	false	none	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  		325646	3008	325646	D016572
aliskiren	Cyclosporine	11	11	false	none	Concomitant use of aliskiren with cyclosporine is not recommended.  		325646	3008	325646	D016572
aliskiren	Cyclosporine	11	11	false	none	Concomitant use of aliskiren with cyclosporine is not recommended.  		325646	3008	325646	D016572
aliskiren	Cyclosporine	12	10	false	none	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		325646	3008	325646	D016572
aliskiren	Cyclosporine	12	10	false	none	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		325646	3008	325646	D016572
aliskiren	Cyclosporine	12	11	false	none	Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		325646	3008	325646	D016572
aliskiren	Cyclosporine	12	11	false	none	Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		325646	3008	325646	D016572
aliskiren	amlodipine	12	14	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	17767	325646	D017311
aliskiren	amlodipine	12	14	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	17767	325646	D017311
aliskiren	amlodipine	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	17767	325646	D017311
aliskiren	amlodipine	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	17767	325646	D017311
aliskiren	amlodipine	15	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		325646	17767	325646	D017311
aliskiren	amlodipine	15	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		325646	17767	325646	D017311
aliskiren	amlodipine	17	18	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	17767	325646	D017311
aliskiren	amlodipine	17	18	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	17767	325646	D017311
aliskiren	amlodipine	16	18	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	17767	325646	D017311
aliskiren	amlodipine	16	18	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	17767	325646	D017311
aliskiren	amlodipine	16	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		325646	17767	325646	D017311
aliskiren	amlodipine	16	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		325646	17767	325646	D017311
aliskiren	amlodipine	19	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		325646	17767	325646	D017311
aliskiren	amlodipine	19	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		325646	17767	325646	D017311
aliskiren	amlodipine	18	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	17767	325646	D017311
aliskiren	amlodipine	18	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	17767	325646	D017311
aliskiren	lovastatin	12	14	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	6472	325646	6472
aliskiren	lovastatin	12	14	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	6472	325646	6472
aliskiren	lovastatin	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	6472	325646	6472
aliskiren	lovastatin	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	6472	325646	6472
aliskiren	lovastatin	15	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		325646	6472	325646	6472
aliskiren	lovastatin	15	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		325646	6472	325646	6472
aliskiren	lovastatin	17	18	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	6472	325646	6472
aliskiren	lovastatin	17	18	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	6472	325646	6472
aliskiren	lovastatin	16	18	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	6472	325646	6472
aliskiren	lovastatin	16	18	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	6472	325646	6472
aliskiren	lovastatin	16	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		325646	6472	325646	6472
aliskiren	lovastatin	16	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		325646	6472	325646	6472
aliskiren	lovastatin	19	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		325646	6472	325646	6472
aliskiren	lovastatin	19	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		325646	6472	325646	6472
aliskiren	lovastatin	18	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	6472	325646	6472
aliskiren	lovastatin	18	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	6472	325646	6472
aliskiren	celecoxib	12	14	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	140587	325646	C105934
aliskiren	celecoxib	12	14	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	140587	325646	C105934
aliskiren	celecoxib	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	140587	325646	C105934
aliskiren	celecoxib	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	140587	325646	C105934
aliskiren	celecoxib	15	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		325646	140587	325646	C105934
aliskiren	celecoxib	15	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		325646	140587	325646	C105934
aliskiren	celecoxib	17	18	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	140587	325646	C105934
aliskiren	celecoxib	17	18	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	140587	325646	C105934
aliskiren	celecoxib	16	18	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	140587	325646	C105934
aliskiren	celecoxib	16	18	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	140587	325646	C105934
aliskiren	celecoxib	16	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		325646	140587	325646	C105934
aliskiren	celecoxib	16	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		325646	140587	325646	C105934
aliskiren	celecoxib	19	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		325646	140587	325646	C105934
aliskiren	celecoxib	19	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		325646	140587	325646	C105934
aliskiren	celecoxib	18	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	140587	325646	C105934
aliskiren	celecoxib	18	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	140587	325646	C105934
aliskiren	Furosemide	12	14	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	4603	325646	4603
aliskiren	Furosemide	12	14	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	4603	325646	4603
aliskiren	Furosemide	14	16	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		325646	4603	325646	4603
aliskiren	Furosemide	14	16	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		325646	4603	325646	4603
aliskiren	Furosemide	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	4603	325646	4603
aliskiren	Furosemide	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	4603	325646	4603
aliskiren	Furosemide	15	17	true	positive	7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  		325646	4603	325646	4603
aliskiren	Furosemide	15	17	true	positive	7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  		325646	4603	325646	4603
aliskiren	Furosemide	15	16	true	positive	7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		325646	4603	325646	4603
aliskiren	Furosemide	15	16	true	positive	7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		325646	4603	325646	4603
aliskiren	Furosemide	15	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		325646	4603	325646	4603
aliskiren	Furosemide	15	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		325646	4603	325646	4603
aliskiren	Furosemide	17	17	true	positive	Patients receiving furosemide could find its effect diminished after starting aliskiren.  		325646	4603	325646	4603
aliskiren	Furosemide	17	17	true	positive	Patients receiving furosemide could find its effect diminished after starting aliskiren.  		325646	4603	325646	4603
aliskiren	Furosemide	17	16	true	positive	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  		325646	4603	325646	4603
aliskiren	Furosemide	17	16	true	positive	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  		325646	4603	325646	4603
aliskiren	Furosemide	16	17	true	positive	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  		325646	4603	325646	4603
aliskiren	Furosemide	16	17	true	positive	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  		325646	4603	325646	4603
aliskiren	Furosemide	16	16	true	positive	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		325646	4603	325646	4603
aliskiren	Furosemide	16	16	true	positive	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		325646	4603	325646	4603
aliskiren	Furosemide	16	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		325646	4603	325646	4603
aliskiren	Furosemide	16	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		325646	4603	325646	4603
aliskiren	Furosemide	19	17	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		325646	4603	325646	4603
aliskiren	Furosemide	19	17	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		325646	4603	325646	4603
aliskiren	Furosemide	18	17	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	4603	325646	4603
aliskiren	Furosemide	18	17	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	4603	325646	4603
aliskiren	Furosemide	18	16	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	4603	325646	4603
aliskiren	Furosemide	18	16	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	4603	325646	4603
aliskiren	cyclosporine	8	10	false	none	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		325646	3008	325646	D016572
aliskiren	cyclosporine	8	10	false	none	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		325646	3008	325646	D016572
aliskiren	cyclosporine	9	10	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		325646	3008	325646	D016572
aliskiren	cyclosporine	9	10	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		325646	3008	325646	D016572
aliskiren	cyclosporine	9	11	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  		325646	3008	325646	D016572
aliskiren	cyclosporine	9	11	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  		325646	3008	325646	D016572
aliskiren	cyclosporine	10	10	true	positive	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		325646	3008	325646	D016572
aliskiren	cyclosporine	10	10	true	positive	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		325646	3008	325646	D016572
aliskiren	cyclosporine	10	11	false	none	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  		325646	3008	325646	D016572
aliskiren	cyclosporine	10	11	false	none	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  		325646	3008	325646	D016572
aliskiren	cyclosporine	11	10	false	none	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  		325646	3008	325646	D016572
aliskiren	cyclosporine	11	10	false	none	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  		325646	3008	325646	D016572
aliskiren	cyclosporine	11	11	false	none	Concomitant use of aliskiren with cyclosporine is not recommended.  		325646	3008	325646	D016572
aliskiren	cyclosporine	11	11	false	none	Concomitant use of aliskiren with cyclosporine is not recommended.  		325646	3008	325646	D016572
aliskiren	cyclosporine	12	10	false	none	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		325646	3008	325646	D016572
aliskiren	cyclosporine	12	10	false	none	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		325646	3008	325646	D016572
aliskiren	cyclosporine	12	11	false	none	Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		325646	3008	325646	D016572
aliskiren	cyclosporine	12	11	false	none	Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		325646	3008	325646	D016572
aliskiren	hydrochlorothiazide	12	14	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	5487	325646	D006852
aliskiren	hydrochlorothiazide	12	14	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	5487	325646	D006852
aliskiren	hydrochlorothiazide	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	5487	325646	D006852
aliskiren	hydrochlorothiazide	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	5487	325646	D006852
aliskiren	hydrochlorothiazide	15	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		325646	5487	325646	D006852
aliskiren	hydrochlorothiazide	15	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		325646	5487	325646	D006852
aliskiren	hydrochlorothiazide	17	18	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	5487	325646	D006852
aliskiren	hydrochlorothiazide	17	18	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	5487	325646	D006852
aliskiren	hydrochlorothiazide	16	18	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	5487	325646	D006852
aliskiren	hydrochlorothiazide	16	18	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	5487	325646	D006852
aliskiren	hydrochlorothiazide	16	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		325646	5487	325646	D006852
aliskiren	hydrochlorothiazide	16	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		325646	5487	325646	D006852
aliskiren	hydrochlorothiazide	19	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		325646	5487	325646	D006852
aliskiren	hydrochlorothiazide	19	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		325646	5487	325646	D006852
aliskiren	hydrochlorothiazide	18	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	5487	325646	D006852
aliskiren	hydrochlorothiazide	18	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	5487	325646	D006852
aliskiren	Irbesartan	1	2	false	none	7  DRUG INTERACTIONS    7.1 Effects of Other Drugs on Aliskiren    Based on in vitro studies, aliskiren is metabolized by CYP 3A4.  Irbesartan: Coadministration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.  		325646	83818	325646	83818
aliskiren	Irbesartan	1	2	false	none	7  DRUG INTERACTIONS    7.1 Effects of Other Drugs on Aliskiren    Based on in vitro studies, aliskiren is metabolized by CYP 3A4.  Irbesartan: Coadministration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.  		325646	83818	325646	83818
aliskiren	Irbesartan	2	2	true	positive	Irbesartan: Coadministration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.  		325646	83818	325646	83818
aliskiren	Irbesartan	2	2	true	positive	Irbesartan: Coadministration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.  		325646	83818	325646	83818
aliskiren	Irbesartan	3	2	true	positive	Irbesartan: Coadministration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.  P-glycoprotein Effects: Pgp (MDR1/Mdr1a/1b) was found to be the major efflux system involved in absorption and disposition of aliskiren in preclinical studies.  		325646	83818	325646	83818
aliskiren	Irbesartan	3	2	true	positive	Irbesartan: Coadministration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.  P-glycoprotein Effects: Pgp (MDR1/Mdr1a/1b) was found to be the major efflux system involved in absorption and disposition of aliskiren in preclinical studies.  		325646	83818	325646	83818
aliskiren	Atorvastatin	3	5	false	none	P-glycoprotein Effects: Pgp (MDR1/Mdr1a/1b) was found to be the major efflux system involved in absorption and disposition of aliskiren in preclinical studies.  The potential for drug interactions at the Pgp site will likely depend on the degree of inhibition of this transporter.  Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  		325646	83367	325646	C065179
aliskiren	Atorvastatin	3	5	false	none	P-glycoprotein Effects: Pgp (MDR1/Mdr1a/1b) was found to be the major efflux system involved in absorption and disposition of aliskiren in preclinical studies.  The potential for drug interactions at the Pgp site will likely depend on the degree of inhibition of this transporter.  Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  		325646	83367	325646	C065179
aliskiren	Atorvastatin	5	5	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  		325646	83367	325646	C065179
aliskiren	Atorvastatin	5	5	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  		325646	83367	325646	C065179
aliskiren	Atorvastatin	6	5	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  		325646	83367	325646	C065179
aliskiren	Atorvastatin	6	5	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  		325646	83367	325646	C065179
aliskiren	Atorvastatin	7	5	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  		325646	83367	325646	C065179
aliskiren	Atorvastatin	7	5	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  		325646	83367	325646	C065179
aliskiren	Atorvastatin	17	18	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	83367	325646	C065179
aliskiren	Atorvastatin	17	18	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	83367	325646	C065179
aliskiren	Atorvastatin	16	18	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	83367	325646	C065179
aliskiren	Atorvastatin	16	18	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	83367	325646	C065179
aliskiren	Atorvastatin	19	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		325646	83367	325646	C065179
aliskiren	Atorvastatin	19	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		325646	83367	325646	C065179
aliskiren	Atorvastatin	18	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	83367	325646	C065179
aliskiren	Atorvastatin	18	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	83367	325646	C065179
Ketoconazole	atorvastatin	6	5	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  		6135	83367	D007654	C065179
Ketoconazole	atorvastatin	6	5	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  		6135	83367	D007654	C065179
Ketoconazole	Itraconazole	6	8	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  		6135	28031	D007654	D017964
Ketoconazole	Itraconazole	6	8	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  		6135	28031	D007654	D017964
Ketoconazole	itraconazole	6	8	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  		6135	28031	D007654	D017964
Ketoconazole	itraconazole	6	8	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  		6135	28031	D007654	D017964
Ketoconazole	Aliskiren	6	5	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  		6135	325646	D007654	325646
Ketoconazole	Aliskiren	6	5	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  		6135	325646	D007654	325646
Ketoconazole	Aliskiren	6	6	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  		6135	325646	D007654	325646
Ketoconazole	Aliskiren	6	6	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  		6135	325646	D007654	325646
Ketoconazole	Aliskiren	6	7	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  		6135	325646	D007654	325646
Ketoconazole	Aliskiren	6	7	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  		6135	325646	D007654	325646
Ketoconazole	Aliskiren	6	8	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  		6135	325646	D007654	325646
Ketoconazole	Aliskiren	6	8	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  		6135	325646	D007654	325646
Ketoconazole	Atorvastatin	6	5	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  		6135	83367	D007654	C065179
Ketoconazole	Atorvastatin	6	5	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  		6135	83367	D007654	C065179
irbesartan	Aliskiren	2	1	false	none	7  DRUG INTERACTIONS    7.1 Effects of Other Drugs on Aliskiren    Based on in vitro studies, aliskiren is metabolized by CYP 3A4.  Irbesartan: Coadministration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.  		83818	325646	83818	325646
irbesartan	Aliskiren	2	1	false	none	7  DRUG INTERACTIONS    7.1 Effects of Other Drugs on Aliskiren    Based on in vitro studies, aliskiren is metabolized by CYP 3A4.  Irbesartan: Coadministration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.  		83818	325646	83818	325646
irbesartan	Aliskiren	2	2	true	positive	Irbesartan: Coadministration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.  		83818	325646	83818	325646
irbesartan	Aliskiren	2	2	true	positive	Irbesartan: Coadministration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.  		83818	325646	83818	325646
irbesartan	Aliskiren	2	3	true	positive	Irbesartan: Coadministration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.  P-glycoprotein Effects: Pgp (MDR1/Mdr1a/1b) was found to be the major efflux system involved in absorption and disposition of aliskiren in preclinical studies.  		83818	325646	83818	325646
irbesartan	Aliskiren	2	3	true	positive	Irbesartan: Coadministration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.  P-glycoprotein Effects: Pgp (MDR1/Mdr1a/1b) was found to be the major efflux system involved in absorption and disposition of aliskiren in preclinical studies.  		83818	325646	83818	325646
atorvastatin	warfarin	18	19	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		83367	11289	C065179	D014859
atorvastatin	warfarin	18	19	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		83367	11289	C065179	D014859
atorvastatin	digoxin	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		83367	3407	C065179	3407
atorvastatin	digoxin	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		83367	3407	C065179	3407
atorvastatin	atenolol	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		83367	1202	C065179	D001262
atorvastatin	atenolol	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		83367	1202	C065179	D001262
atorvastatin	metformin	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		83367	6809	C065179	6809
atorvastatin	metformin	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		83367	6809	C065179	6809
atorvastatin	ketoconazole	5	6	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  		83367	6135	C065179	D007654
atorvastatin	ketoconazole	5	6	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  		83367	6135	C065179	D007654
atorvastatin	ramipril	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		83367	35296	C065179	D017257
atorvastatin	ramipril	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		83367	35296	C065179	D017257
atorvastatin	amlodipine	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		83367	17767	C065179	D017311
atorvastatin	amlodipine	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		83367	17767	C065179	D017311
atorvastatin	lovastatin	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		83367	6472	C065179	6472
atorvastatin	lovastatin	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		83367	6472	C065179	6472
atorvastatin	celecoxib	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		83367	140587	C065179	C105934
atorvastatin	celecoxib	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		83367	140587	C065179	C105934
atorvastatin	Furosemide	18	17	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		83367	4603	C065179	4603
atorvastatin	Furosemide	18	17	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		83367	4603	C065179	4603
atorvastatin	Furosemide	18	16	false	none	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		83367	4603	C065179	4603
atorvastatin	Furosemide	18	16	false	none	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		83367	4603	C065179	4603
atorvastatin	Aliskiren	18	17	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		83367	325646	C065179	325646
atorvastatin	Aliskiren	18	17	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		83367	325646	C065179	325646
atorvastatin	Aliskiren	18	16	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		83367	325646	C065179	325646
atorvastatin	Aliskiren	18	16	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		83367	325646	C065179	325646
atorvastatin	Aliskiren	18	19	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		83367	325646	C065179	325646
atorvastatin	Aliskiren	18	19	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		83367	325646	C065179	325646
atorvastatin	Aliskiren	18	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		83367	325646	C065179	325646
atorvastatin	Aliskiren	18	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		83367	325646	C065179	325646
atorvastatin	Aliskiren	5	3	false	none	P-glycoprotein Effects: Pgp (MDR1/Mdr1a/1b) was found to be the major efflux system involved in absorption and disposition of aliskiren in preclinical studies.  The potential for drug interactions at the Pgp site will likely depend on the degree of inhibition of this transporter.  Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  		83367	325646	C065179	325646
atorvastatin	Aliskiren	5	3	false	none	P-glycoprotein Effects: Pgp (MDR1/Mdr1a/1b) was found to be the major efflux system involved in absorption and disposition of aliskiren in preclinical studies.  The potential for drug interactions at the Pgp site will likely depend on the degree of inhibition of this transporter.  Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  		83367	325646	C065179	325646
atorvastatin	Aliskiren	5	5	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  		83367	325646	C065179	325646
atorvastatin	Aliskiren	5	5	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  		83367	325646	C065179	325646
atorvastatin	Aliskiren	5	6	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  		83367	325646	C065179	325646
atorvastatin	Aliskiren	5	6	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  		83367	325646	C065179	325646
atorvastatin	Aliskiren	5	7	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  		83367	325646	C065179	325646
atorvastatin	Aliskiren	5	7	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  		83367	325646	C065179	325646
atorvastatin	hydrochlorothiazide	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		83367	5487	C065179	D006852
atorvastatin	hydrochlorothiazide	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		83367	5487	C065179	D006852
Itraconazole	ketoconazole	8	6	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  		28031	6135	D017964	D007654
Itraconazole	ketoconazole	8	6	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  		28031	6135	D017964	D007654
Itraconazole	Cyclosporine	8	10	false	none	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		28031	3008	D017964	D016572
Itraconazole	Cyclosporine	8	10	false	none	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		28031	3008	D017964	D016572
Itraconazole	Cyclosporine	9	10	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		28031	3008	D017964	D016572
Itraconazole	Cyclosporine	9	10	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		28031	3008	D017964	D016572
Itraconazole	Cyclosporine	9	11	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  		28031	3008	D017964	D016572
Itraconazole	Cyclosporine	9	11	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  		28031	3008	D017964	D016572
Itraconazole	cyclosporine	8	10	false	none	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		28031	3008	D017964	D016572
Itraconazole	cyclosporine	8	10	false	none	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		28031	3008	D017964	D016572
Itraconazole	cyclosporine	9	10	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		28031	3008	D017964	D016572
Itraconazole	cyclosporine	9	10	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		28031	3008	D017964	D016572
Itraconazole	cyclosporine	9	11	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  		28031	3008	D017964	D016572
Itraconazole	cyclosporine	9	11	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  		28031	3008	D017964	D016572
Itraconazole	Aliskiren	8	6	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  		28031	325646	D017964	325646
Itraconazole	Aliskiren	8	6	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  		28031	325646	D017964	325646
Itraconazole	Aliskiren	8	7	true	positive	A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  		28031	325646	D017964	325646
Itraconazole	Aliskiren	8	7	true	positive	A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  		28031	325646	D017964	325646
Itraconazole	Aliskiren	8	8	true	positive	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  		28031	325646	D017964	325646
Itraconazole	Aliskiren	8	8	true	positive	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  		28031	325646	D017964	325646
Itraconazole	Aliskiren	8	9	false	none	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  		28031	325646	D017964	325646
Itraconazole	Aliskiren	8	9	false	none	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  		28031	325646	D017964	325646
Itraconazole	Aliskiren	8	10	false	none	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		28031	325646	D017964	325646
Itraconazole	Aliskiren	8	10	false	none	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		28031	325646	D017964	325646
Itraconazole	Aliskiren	9	7	true	positive	A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  		28031	325646	D017964	325646
Itraconazole	Aliskiren	9	7	true	positive	A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  		28031	325646	D017964	325646
Itraconazole	Aliskiren	9	8	false	none	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  		28031	325646	D017964	325646
Itraconazole	Aliskiren	9	8	false	none	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  		28031	325646	D017964	325646
Itraconazole	Aliskiren	9	9	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  		28031	325646	D017964	325646
Itraconazole	Aliskiren	9	9	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  		28031	325646	D017964	325646
Itraconazole	Aliskiren	9	10	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		28031	325646	D017964	325646
Itraconazole	Aliskiren	9	10	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		28031	325646	D017964	325646
Itraconazole	Aliskiren	9	11	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  		28031	325646	D017964	325646
Itraconazole	Aliskiren	9	11	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  		28031	325646	D017964	325646
Verapamil	warfarin	12	14	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11170	11289	11170	D014859
Verapamil	warfarin	12	14	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11170	11289	11170	D014859
Verapamil	digoxin	12	14	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11170	3407	11170	3407
Verapamil	digoxin	12	14	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11170	3407	11170	3407
Verapamil	atenolol	12	14	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11170	1202	11170	D001262
Verapamil	atenolol	12	14	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11170	1202	11170	D001262
Verapamil	metformin	12	14	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11170	6809	11170	6809
Verapamil	metformin	12	14	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11170	6809	11170	6809
Verapamil	ramipril	12	14	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11170	35296	11170	D017257
Verapamil	ramipril	12	14	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11170	35296	11170	D017257
Verapamil	Cyclosporine	12	10	false	none	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		11170	3008	11170	D016572
Verapamil	Cyclosporine	12	10	false	none	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		11170	3008	11170	D016572
Verapamil	Cyclosporine	12	11	false	none	Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		11170	3008	11170	D016572
Verapamil	Cyclosporine	12	11	false	none	Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		11170	3008	11170	D016572
Verapamil	amlodipine	12	14	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11170	17767	11170	D017311
Verapamil	amlodipine	12	14	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11170	17767	11170	D017311
Verapamil	lovastatin	12	14	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11170	6472	11170	6472
Verapamil	lovastatin	12	14	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11170	6472	11170	6472
Verapamil	celecoxib	12	14	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11170	140587	11170	C105934
Verapamil	celecoxib	12	14	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11170	140587	11170	C105934
Verapamil	Furosemide	12	14	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11170	4603	11170	4603
Verapamil	Furosemide	12	14	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11170	4603	11170	4603
Verapamil	cyclosporine	12	10	false	none	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		11170	3008	11170	D016572
Verapamil	cyclosporine	12	10	false	none	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		11170	3008	11170	D016572
Verapamil	cyclosporine	12	11	false	none	Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		11170	3008	11170	D016572
Verapamil	cyclosporine	12	11	false	none	Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		11170	3008	11170	D016572
Verapamil	Aliskiren	12	10	false	none	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		11170	325646	11170	325646
Verapamil	Aliskiren	12	10	false	none	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		11170	325646	11170	325646
Verapamil	Aliskiren	12	11	false	none	Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		11170	325646	11170	325646
Verapamil	Aliskiren	12	11	false	none	Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		11170	325646	11170	325646
Verapamil	Aliskiren	12	12	true	positive	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		11170	325646	11170	325646
Verapamil	Aliskiren	12	12	true	positive	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		11170	325646	11170	325646
Verapamil	Aliskiren	12	14	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11170	325646	11170	325646
Verapamil	Aliskiren	12	14	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11170	325646	11170	325646
Verapamil	hydrochlorothiazide	12	14	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11170	5487	11170	D006852
Verapamil	hydrochlorothiazide	12	14	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11170	5487	11170	D006852
warfarin	digoxin	19	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	3407	D014859	3407
warfarin	digoxin	19	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	3407	D014859	3407
warfarin	digoxin	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	3407	D014859	3407
warfarin	digoxin	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	3407	D014859	3407
warfarin	atenolol	19	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	1202	D014859	D001262
warfarin	atenolol	19	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	1202	D014859	D001262
warfarin	atenolol	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	1202	D014859	D001262
warfarin	atenolol	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	1202	D014859	D001262
warfarin	metformin	19	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	6809	D014859	6809
warfarin	metformin	19	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	6809	D014859	6809
warfarin	metformin	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	6809	D014859	6809
warfarin	metformin	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	6809	D014859	6809
warfarin	verapamil	14	12	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	11170	D014859	11170
warfarin	verapamil	14	12	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	11170	D014859	11170
warfarin	ramipril	19	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	35296	D014859	D017257
warfarin	ramipril	19	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	35296	D014859	D017257
warfarin	ramipril	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	35296	D014859	D017257
warfarin	ramipril	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	35296	D014859	D017257
warfarin	amlodipine	19	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	17767	D014859	D017311
warfarin	amlodipine	19	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	17767	D014859	D017311
warfarin	amlodipine	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	17767	D014859	D017311
warfarin	amlodipine	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	17767	D014859	D017311
warfarin	lovastatin	19	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	6472	D014859	6472
warfarin	lovastatin	19	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	6472	D014859	6472
warfarin	lovastatin	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	6472	D014859	6472
warfarin	lovastatin	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	6472	D014859	6472
warfarin	celecoxib	19	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	140587	D014859	C105934
warfarin	celecoxib	19	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	140587	D014859	C105934
warfarin	celecoxib	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	140587	D014859	C105934
warfarin	celecoxib	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	140587	D014859	C105934
warfarin	Furosemide	19	17	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	4603	D014859	4603
warfarin	Furosemide	19	17	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	4603	D014859	4603
warfarin	Furosemide	14	16	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		11289	4603	D014859	4603
warfarin	Furosemide	14	16	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		11289	4603	D014859	4603
warfarin	Furosemide	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	4603	D014859	4603
warfarin	Furosemide	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	4603	D014859	4603
warfarin	Aliskiren	19	17	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	325646	D014859	325646
warfarin	Aliskiren	19	17	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	325646	D014859	325646
warfarin	Aliskiren	19	19	true	negative	Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	325646	D014859	325646
warfarin	Aliskiren	19	19	true	negative	Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	325646	D014859	325646
warfarin	Aliskiren	19	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	325646	D014859	325646
warfarin	Aliskiren	19	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	325646	D014859	325646
warfarin	Aliskiren	14	12	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	325646	D014859	325646
warfarin	Aliskiren	14	12	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	325646	D014859	325646
warfarin	Aliskiren	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	325646	D014859	325646
warfarin	Aliskiren	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	325646	D014859	325646
warfarin	Aliskiren	14	15	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		11289	325646	D014859	325646
warfarin	Aliskiren	14	15	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		11289	325646	D014859	325646
warfarin	Aliskiren	14	16	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		11289	325646	D014859	325646
warfarin	Aliskiren	14	16	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		11289	325646	D014859	325646
warfarin	hydrochlorothiazide	19	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	5487	D014859	D006852
warfarin	hydrochlorothiazide	19	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	5487	D014859	D006852
warfarin	hydrochlorothiazide	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	5487	D014859	D006852
warfarin	hydrochlorothiazide	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11289	5487	D014859	D006852
warfarin	Atorvastatin	19	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	83367	D014859	C065179
warfarin	Atorvastatin	19	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		11289	83367	D014859	C065179
digoxin	atenolol	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		3407	1202	3407	D001262
digoxin	atenolol	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		3407	1202	3407	D001262
digoxin	atenolol	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		3407	1202	3407	D001262
digoxin	atenolol	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		3407	1202	3407	D001262
digoxin	metformin	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		3407	6809	3407	6809
digoxin	metformin	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		3407	6809	3407	6809
digoxin	metformin	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		3407	6809	3407	6809
digoxin	metformin	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		3407	6809	3407	6809
digoxin	verapamil	14	12	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		3407	11170	3407	11170
digoxin	verapamil	14	12	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		3407	11170	3407	11170
digoxin	ramipril	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		3407	35296	3407	D017257
digoxin	ramipril	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		3407	35296	3407	D017257
digoxin	ramipril	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		3407	35296	3407	D017257
digoxin	ramipril	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		3407	35296	3407	D017257
digoxin	amlodipine	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		3407	17767	3407	D017311
digoxin	amlodipine	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		3407	17767	3407	D017311
digoxin	amlodipine	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		3407	17767	3407	D017311
digoxin	amlodipine	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		3407	17767	3407	D017311
digoxin	lovastatin	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		3407	6472	3407	6472
digoxin	lovastatin	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		3407	6472	3407	6472
digoxin	lovastatin	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		3407	6472	3407	6472
digoxin	lovastatin	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		3407	6472	3407	6472
digoxin	celecoxib	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		3407	140587	3407	C105934
digoxin	celecoxib	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		3407	140587	3407	C105934
digoxin	celecoxib	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		3407	140587	3407	C105934
digoxin	celecoxib	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		3407	140587	3407	C105934
digoxin	Furosemide	18	17	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		3407	4603	3407	4603
digoxin	Furosemide	18	17	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		3407	4603	3407	4603
digoxin	Furosemide	18	16	false	none	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		3407	4603	3407	4603
digoxin	Furosemide	18	16	false	none	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		3407	4603	3407	4603
digoxin	Furosemide	14	16	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		3407	4603	3407	4603
digoxin	Furosemide	14	16	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		3407	4603	3407	4603
digoxin	Furosemide	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		3407	4603	3407	4603
digoxin	Furosemide	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		3407	4603	3407	4603
digoxin	Aliskiren	18	17	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		3407	325646	3407	325646
digoxin	Aliskiren	18	17	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		3407	325646	3407	325646
digoxin	Aliskiren	18	16	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		3407	325646	3407	325646
digoxin	Aliskiren	18	16	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		3407	325646	3407	325646
digoxin	Aliskiren	18	19	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		3407	325646	3407	325646
digoxin	Aliskiren	18	19	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		3407	325646	3407	325646
digoxin	Aliskiren	18	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		3407	325646	3407	325646
digoxin	Aliskiren	18	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		3407	325646	3407	325646
digoxin	Aliskiren	14	12	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		3407	325646	3407	325646
digoxin	Aliskiren	14	12	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		3407	325646	3407	325646
digoxin	Aliskiren	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		3407	325646	3407	325646
digoxin	Aliskiren	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		3407	325646	3407	325646
digoxin	Aliskiren	14	15	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		3407	325646	3407	325646
digoxin	Aliskiren	14	15	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		3407	325646	3407	325646
digoxin	Aliskiren	14	16	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		3407	325646	3407	325646
digoxin	Aliskiren	14	16	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		3407	325646	3407	325646
digoxin	hydrochlorothiazide	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		3407	5487	3407	D006852
digoxin	hydrochlorothiazide	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		3407	5487	3407	D006852
digoxin	hydrochlorothiazide	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		3407	5487	3407	D006852
digoxin	hydrochlorothiazide	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		3407	5487	3407	D006852
digoxin	Atorvastatin	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		3407	83367	3407	C065179
digoxin	Atorvastatin	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		3407	83367	3407	C065179
atenolol	metformin	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		1202	6809	D001262	6809
atenolol	metformin	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		1202	6809	D001262	6809
atenolol	metformin	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		1202	6809	D001262	6809
atenolol	metformin	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		1202	6809	D001262	6809
atenolol	verapamil	14	12	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		1202	11170	D001262	11170
atenolol	verapamil	14	12	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		1202	11170	D001262	11170
atenolol	ramipril	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		1202	35296	D001262	D017257
atenolol	ramipril	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		1202	35296	D001262	D017257
atenolol	ramipril	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		1202	35296	D001262	D017257
atenolol	ramipril	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		1202	35296	D001262	D017257
atenolol	amlodipine	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		1202	17767	D001262	D017311
atenolol	amlodipine	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		1202	17767	D001262	D017311
atenolol	amlodipine	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		1202	17767	D001262	D017311
atenolol	amlodipine	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		1202	17767	D001262	D017311
atenolol	lovastatin	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		1202	6472	D001262	6472
atenolol	lovastatin	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		1202	6472	D001262	6472
atenolol	lovastatin	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		1202	6472	D001262	6472
atenolol	lovastatin	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		1202	6472	D001262	6472
atenolol	celecoxib	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		1202	140587	D001262	C105934
atenolol	celecoxib	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		1202	140587	D001262	C105934
atenolol	celecoxib	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		1202	140587	D001262	C105934
atenolol	celecoxib	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		1202	140587	D001262	C105934
atenolol	Furosemide	18	17	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		1202	4603	D001262	4603
atenolol	Furosemide	18	17	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		1202	4603	D001262	4603
atenolol	Furosemide	18	16	false	none	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		1202	4603	D001262	4603
atenolol	Furosemide	18	16	false	none	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		1202	4603	D001262	4603
atenolol	Furosemide	14	16	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		1202	4603	D001262	4603
atenolol	Furosemide	14	16	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		1202	4603	D001262	4603
atenolol	Furosemide	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		1202	4603	D001262	4603
atenolol	Furosemide	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		1202	4603	D001262	4603
atenolol	Aliskiren	18	17	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		1202	325646	D001262	325646
atenolol	Aliskiren	18	17	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		1202	325646	D001262	325646
atenolol	Aliskiren	18	16	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		1202	325646	D001262	325646
atenolol	Aliskiren	18	16	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		1202	325646	D001262	325646
atenolol	Aliskiren	18	19	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		1202	325646	D001262	325646
atenolol	Aliskiren	18	19	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		1202	325646	D001262	325646
atenolol	Aliskiren	18	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		1202	325646	D001262	325646
atenolol	Aliskiren	18	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		1202	325646	D001262	325646
atenolol	Aliskiren	14	12	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		1202	325646	D001262	325646
atenolol	Aliskiren	14	12	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		1202	325646	D001262	325646
atenolol	Aliskiren	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		1202	325646	D001262	325646
atenolol	Aliskiren	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		1202	325646	D001262	325646
atenolol	Aliskiren	14	15	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		1202	325646	D001262	325646
atenolol	Aliskiren	14	15	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		1202	325646	D001262	325646
atenolol	Aliskiren	14	16	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		1202	325646	D001262	325646
atenolol	Aliskiren	14	16	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		1202	325646	D001262	325646
atenolol	hydrochlorothiazide	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		1202	5487	D001262	D006852
atenolol	hydrochlorothiazide	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		1202	5487	D001262	D006852
atenolol	hydrochlorothiazide	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		1202	5487	D001262	D006852
atenolol	hydrochlorothiazide	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		1202	5487	D001262	D006852
atenolol	Atorvastatin	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		1202	83367	D001262	C065179
atenolol	Atorvastatin	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		1202	83367	D001262	C065179
itraconazole	ketoconazole	8	6	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  		28031	6135	D017964	D007654
itraconazole	ketoconazole	8	6	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  		28031	6135	D017964	D007654
itraconazole	Cyclosporine	8	10	false	none	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		28031	3008	D017964	D016572
itraconazole	Cyclosporine	8	10	false	none	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		28031	3008	D017964	D016572
itraconazole	Cyclosporine	9	10	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		28031	3008	D017964	D016572
itraconazole	Cyclosporine	9	10	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		28031	3008	D017964	D016572
itraconazole	Cyclosporine	9	11	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  		28031	3008	D017964	D016572
itraconazole	Cyclosporine	9	11	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  		28031	3008	D017964	D016572
itraconazole	cyclosporine	8	10	false	none	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		28031	3008	D017964	D016572
itraconazole	cyclosporine	8	10	false	none	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		28031	3008	D017964	D016572
itraconazole	cyclosporine	9	10	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		28031	3008	D017964	D016572
itraconazole	cyclosporine	9	10	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		28031	3008	D017964	D016572
itraconazole	cyclosporine	9	11	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  		28031	3008	D017964	D016572
itraconazole	cyclosporine	9	11	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  		28031	3008	D017964	D016572
itraconazole	Aliskiren	8	6	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  		28031	325646	D017964	325646
itraconazole	Aliskiren	8	6	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  		28031	325646	D017964	325646
itraconazole	Aliskiren	8	7	true	positive	A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  		28031	325646	D017964	325646
itraconazole	Aliskiren	8	7	true	positive	A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  		28031	325646	D017964	325646
itraconazole	Aliskiren	8	8	true	positive	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  		28031	325646	D017964	325646
itraconazole	Aliskiren	8	8	true	positive	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  		28031	325646	D017964	325646
itraconazole	Aliskiren	8	9	false	none	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  		28031	325646	D017964	325646
itraconazole	Aliskiren	8	9	false	none	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  		28031	325646	D017964	325646
itraconazole	Aliskiren	8	10	false	none	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		28031	325646	D017964	325646
itraconazole	Aliskiren	8	10	false	none	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		28031	325646	D017964	325646
itraconazole	Aliskiren	9	7	true	positive	A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  		28031	325646	D017964	325646
itraconazole	Aliskiren	9	7	true	positive	A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  		28031	325646	D017964	325646
itraconazole	Aliskiren	9	8	false	none	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  		28031	325646	D017964	325646
itraconazole	Aliskiren	9	8	false	none	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  		28031	325646	D017964	325646
itraconazole	Aliskiren	9	9	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  		28031	325646	D017964	325646
itraconazole	Aliskiren	9	9	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  		28031	325646	D017964	325646
itraconazole	Aliskiren	9	10	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		28031	325646	D017964	325646
itraconazole	Aliskiren	9	10	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		28031	325646	D017964	325646
itraconazole	Aliskiren	9	11	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  		28031	325646	D017964	325646
itraconazole	Aliskiren	9	11	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  		28031	325646	D017964	325646
metformin	verapamil	14	12	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		6809	11170	6809	11170
metformin	verapamil	14	12	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		6809	11170	6809	11170
metformin	ramipril	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		6809	35296	6809	D017257
metformin	ramipril	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		6809	35296	6809	D017257
metformin	ramipril	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		6809	35296	6809	D017257
metformin	ramipril	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		6809	35296	6809	D017257
metformin	amlodipine	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		6809	17767	6809	D017311
metformin	amlodipine	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		6809	17767	6809	D017311
metformin	amlodipine	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		6809	17767	6809	D017311
metformin	amlodipine	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		6809	17767	6809	D017311
metformin	lovastatin	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		6809	6472	6809	6472
metformin	lovastatin	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		6809	6472	6809	6472
metformin	lovastatin	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		6809	6472	6809	6472
metformin	lovastatin	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		6809	6472	6809	6472
metformin	celecoxib	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		6809	140587	6809	C105934
metformin	celecoxib	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		6809	140587	6809	C105934
metformin	celecoxib	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		6809	140587	6809	C105934
metformin	celecoxib	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		6809	140587	6809	C105934
metformin	Furosemide	18	17	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		6809	4603	6809	4603
metformin	Furosemide	18	17	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		6809	4603	6809	4603
metformin	Furosemide	18	16	false	none	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		6809	4603	6809	4603
metformin	Furosemide	18	16	false	none	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		6809	4603	6809	4603
metformin	Furosemide	14	16	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		6809	4603	6809	4603
metformin	Furosemide	14	16	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		6809	4603	6809	4603
metformin	Furosemide	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		6809	4603	6809	4603
metformin	Furosemide	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		6809	4603	6809	4603
metformin	Aliskiren	18	17	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		6809	325646	6809	325646
metformin	Aliskiren	18	17	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		6809	325646	6809	325646
metformin	Aliskiren	18	16	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		6809	325646	6809	325646
metformin	Aliskiren	18	16	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		6809	325646	6809	325646
metformin	Aliskiren	18	19	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		6809	325646	6809	325646
metformin	Aliskiren	18	19	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		6809	325646	6809	325646
metformin	Aliskiren	18	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		6809	325646	6809	325646
metformin	Aliskiren	18	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		6809	325646	6809	325646
metformin	Aliskiren	14	12	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		6809	325646	6809	325646
metformin	Aliskiren	14	12	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		6809	325646	6809	325646
metformin	Aliskiren	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		6809	325646	6809	325646
metformin	Aliskiren	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		6809	325646	6809	325646
metformin	Aliskiren	14	15	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		6809	325646	6809	325646
metformin	Aliskiren	14	15	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		6809	325646	6809	325646
metformin	Aliskiren	14	16	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		6809	325646	6809	325646
metformin	Aliskiren	14	16	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		6809	325646	6809	325646
metformin	hydrochlorothiazide	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		6809	5487	6809	D006852
metformin	hydrochlorothiazide	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		6809	5487	6809	D006852
metformin	hydrochlorothiazide	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		6809	5487	6809	D006852
metformin	hydrochlorothiazide	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		6809	5487	6809	D006852
metformin	Atorvastatin	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		6809	83367	6809	C065179
metformin	Atorvastatin	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		6809	83367	6809	C065179
ketoconazole	Aliskiren	6	5	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  		6135	325646	D007654	325646
ketoconazole	Aliskiren	6	5	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  		6135	325646	D007654	325646
ketoconazole	Aliskiren	6	6	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  		6135	325646	D007654	325646
ketoconazole	Aliskiren	6	6	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  		6135	325646	D007654	325646
ketoconazole	Aliskiren	6	7	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  		6135	325646	D007654	325646
ketoconazole	Aliskiren	6	7	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  		6135	325646	D007654	325646
ketoconazole	Aliskiren	6	8	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  		6135	325646	D007654	325646
ketoconazole	Aliskiren	6	8	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  		6135	325646	D007654	325646
ketoconazole	Atorvastatin	6	5	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  		6135	83367	D007654	C065179
ketoconazole	Atorvastatin	6	5	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  		6135	83367	D007654	C065179
verapamil	ramipril	12	14	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11170	35296	11170	D017257
verapamil	ramipril	12	14	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11170	35296	11170	D017257
verapamil	Cyclosporine	12	10	false	none	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		11170	3008	11170	D016572
verapamil	Cyclosporine	12	10	false	none	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		11170	3008	11170	D016572
verapamil	Cyclosporine	12	11	false	none	Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		11170	3008	11170	D016572
verapamil	Cyclosporine	12	11	false	none	Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		11170	3008	11170	D016572
verapamil	amlodipine	12	14	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11170	17767	11170	D017311
verapamil	amlodipine	12	14	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11170	17767	11170	D017311
verapamil	lovastatin	12	14	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11170	6472	11170	6472
verapamil	lovastatin	12	14	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11170	6472	11170	6472
verapamil	celecoxib	12	14	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11170	140587	11170	C105934
verapamil	celecoxib	12	14	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11170	140587	11170	C105934
verapamil	Furosemide	12	14	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11170	4603	11170	4603
verapamil	Furosemide	12	14	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11170	4603	11170	4603
verapamil	cyclosporine	12	10	false	none	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		11170	3008	11170	D016572
verapamil	cyclosporine	12	10	false	none	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		11170	3008	11170	D016572
verapamil	cyclosporine	12	11	false	none	Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		11170	3008	11170	D016572
verapamil	cyclosporine	12	11	false	none	Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		11170	3008	11170	D016572
verapamil	Aliskiren	12	10	false	none	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		11170	325646	11170	325646
verapamil	Aliskiren	12	10	false	none	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		11170	325646	11170	325646
verapamil	Aliskiren	12	11	false	none	Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		11170	325646	11170	325646
verapamil	Aliskiren	12	11	false	none	Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		11170	325646	11170	325646
verapamil	Aliskiren	12	12	true	positive	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		11170	325646	11170	325646
verapamil	Aliskiren	12	12	true	positive	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		11170	325646	11170	325646
verapamil	Aliskiren	12	14	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11170	325646	11170	325646
verapamil	Aliskiren	12	14	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11170	325646	11170	325646
verapamil	hydrochlorothiazide	12	14	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11170	5487	11170	D006852
verapamil	hydrochlorothiazide	12	14	false	none	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		11170	5487	11170	D006852
ramipril	amlodipine	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		35296	17767	D017257	D017311
ramipril	amlodipine	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		35296	17767	D017257	D017311
ramipril	amlodipine	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		35296	17767	D017257	D017311
ramipril	amlodipine	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		35296	17767	D017257	D017311
ramipril	lovastatin	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		35296	6472	D017257	6472
ramipril	lovastatin	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		35296	6472	D017257	6472
ramipril	lovastatin	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		35296	6472	D017257	6472
ramipril	lovastatin	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		35296	6472	D017257	6472
ramipril	celecoxib	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		35296	140587	D017257	C105934
ramipril	celecoxib	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		35296	140587	D017257	C105934
ramipril	celecoxib	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		35296	140587	D017257	C105934
ramipril	celecoxib	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		35296	140587	D017257	C105934
ramipril	Furosemide	18	17	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		35296	4603	D017257	4603
ramipril	Furosemide	18	17	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		35296	4603	D017257	4603
ramipril	Furosemide	18	16	false	none	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		35296	4603	D017257	4603
ramipril	Furosemide	18	16	false	none	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		35296	4603	D017257	4603
ramipril	Furosemide	14	16	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		35296	4603	D017257	4603
ramipril	Furosemide	14	16	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		35296	4603	D017257	4603
ramipril	Furosemide	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		35296	4603	D017257	4603
ramipril	Furosemide	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		35296	4603	D017257	4603
ramipril	Aliskiren	18	17	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		35296	325646	D017257	325646
ramipril	Aliskiren	18	17	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		35296	325646	D017257	325646
ramipril	Aliskiren	18	16	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		35296	325646	D017257	325646
ramipril	Aliskiren	18	16	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		35296	325646	D017257	325646
ramipril	Aliskiren	18	19	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		35296	325646	D017257	325646
ramipril	Aliskiren	18	19	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		35296	325646	D017257	325646
ramipril	Aliskiren	18	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		35296	325646	D017257	325646
ramipril	Aliskiren	18	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		35296	325646	D017257	325646
ramipril	Aliskiren	14	12	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		35296	325646	D017257	325646
ramipril	Aliskiren	14	12	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		35296	325646	D017257	325646
ramipril	Aliskiren	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		35296	325646	D017257	325646
ramipril	Aliskiren	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		35296	325646	D017257	325646
ramipril	Aliskiren	14	15	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		35296	325646	D017257	325646
ramipril	Aliskiren	14	15	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		35296	325646	D017257	325646
ramipril	Aliskiren	14	16	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		35296	325646	D017257	325646
ramipril	Aliskiren	14	16	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		35296	325646	D017257	325646
ramipril	hydrochlorothiazide	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		35296	5487	D017257	D006852
ramipril	hydrochlorothiazide	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		35296	5487	D017257	D006852
ramipril	hydrochlorothiazide	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		35296	5487	D017257	D006852
ramipril	hydrochlorothiazide	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		35296	5487	D017257	D006852
ramipril	Atorvastatin	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		35296	83367	D017257	C065179
ramipril	Atorvastatin	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		35296	83367	D017257	C065179
Cyclosporine	Aliskiren	10	8	false	none	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		3008	325646	D016572	325646
Cyclosporine	Aliskiren	10	8	false	none	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		3008	325646	D016572	325646
Cyclosporine	Aliskiren	10	9	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		3008	325646	D016572	325646
Cyclosporine	Aliskiren	10	9	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		3008	325646	D016572	325646
Cyclosporine	Aliskiren	10	10	true	positive	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		3008	325646	D016572	325646
Cyclosporine	Aliskiren	10	10	true	positive	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		3008	325646	D016572	325646
Cyclosporine	Aliskiren	10	11	false	none	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  		3008	325646	D016572	325646
Cyclosporine	Aliskiren	10	11	false	none	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  		3008	325646	D016572	325646
Cyclosporine	Aliskiren	10	12	false	none	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		3008	325646	D016572	325646
Cyclosporine	Aliskiren	10	12	false	none	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		3008	325646	D016572	325646
Cyclosporine	Aliskiren	11	9	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  		3008	325646	D016572	325646
Cyclosporine	Aliskiren	11	9	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  		3008	325646	D016572	325646
Cyclosporine	Aliskiren	11	10	false	none	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  		3008	325646	D016572	325646
Cyclosporine	Aliskiren	11	10	false	none	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  		3008	325646	D016572	325646
Cyclosporine	Aliskiren	11	11	false	none	Concomitant use of aliskiren with cyclosporine is not recommended.  		3008	325646	D016572	325646
Cyclosporine	Aliskiren	11	11	false	none	Concomitant use of aliskiren with cyclosporine is not recommended.  		3008	325646	D016572	325646
Cyclosporine	Aliskiren	11	12	false	none	Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		3008	325646	D016572	325646
Cyclosporine	Aliskiren	11	12	false	none	Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		3008	325646	D016572	325646
amlodipine	lovastatin	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		17767	6472	D017311	6472
amlodipine	lovastatin	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		17767	6472	D017311	6472
amlodipine	lovastatin	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		17767	6472	D017311	6472
amlodipine	lovastatin	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		17767	6472	D017311	6472
amlodipine	celecoxib	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		17767	140587	D017311	C105934
amlodipine	celecoxib	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		17767	140587	D017311	C105934
amlodipine	celecoxib	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		17767	140587	D017311	C105934
amlodipine	celecoxib	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		17767	140587	D017311	C105934
amlodipine	Furosemide	18	17	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		17767	4603	D017311	4603
amlodipine	Furosemide	18	17	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		17767	4603	D017311	4603
amlodipine	Furosemide	18	16	false	none	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		17767	4603	D017311	4603
amlodipine	Furosemide	18	16	false	none	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		17767	4603	D017311	4603
amlodipine	Furosemide	14	16	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		17767	4603	D017311	4603
amlodipine	Furosemide	14	16	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		17767	4603	D017311	4603
amlodipine	Furosemide	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		17767	4603	D017311	4603
amlodipine	Furosemide	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		17767	4603	D017311	4603
amlodipine	Aliskiren	18	17	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		17767	325646	D017311	325646
amlodipine	Aliskiren	18	17	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		17767	325646	D017311	325646
amlodipine	Aliskiren	18	16	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		17767	325646	D017311	325646
amlodipine	Aliskiren	18	16	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		17767	325646	D017311	325646
amlodipine	Aliskiren	18	19	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		17767	325646	D017311	325646
amlodipine	Aliskiren	18	19	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		17767	325646	D017311	325646
amlodipine	Aliskiren	18	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		17767	325646	D017311	325646
amlodipine	Aliskiren	18	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		17767	325646	D017311	325646
amlodipine	Aliskiren	14	12	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		17767	325646	D017311	325646
amlodipine	Aliskiren	14	12	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		17767	325646	D017311	325646
amlodipine	Aliskiren	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		17767	325646	D017311	325646
amlodipine	Aliskiren	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		17767	325646	D017311	325646
amlodipine	Aliskiren	14	15	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		17767	325646	D017311	325646
amlodipine	Aliskiren	14	15	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		17767	325646	D017311	325646
amlodipine	Aliskiren	14	16	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		17767	325646	D017311	325646
amlodipine	Aliskiren	14	16	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		17767	325646	D017311	325646
amlodipine	hydrochlorothiazide	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		17767	5487	D017311	D006852
amlodipine	hydrochlorothiazide	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		17767	5487	D017311	D006852
amlodipine	hydrochlorothiazide	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		17767	5487	D017311	D006852
amlodipine	hydrochlorothiazide	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		17767	5487	D017311	D006852
amlodipine	Atorvastatin	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		17767	83367	D017311	C065179
amlodipine	Atorvastatin	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		17767	83367	D017311	C065179
lovastatin	celecoxib	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		6472	140587	6472	C105934
lovastatin	celecoxib	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		6472	140587	6472	C105934
lovastatin	celecoxib	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		6472	140587	6472	C105934
lovastatin	celecoxib	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		6472	140587	6472	C105934
lovastatin	Furosemide	18	17	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		6472	4603	6472	4603
lovastatin	Furosemide	18	17	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		6472	4603	6472	4603
lovastatin	Furosemide	18	16	false	none	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		6472	4603	6472	4603
lovastatin	Furosemide	18	16	false	none	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		6472	4603	6472	4603
lovastatin	Furosemide	14	16	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		6472	4603	6472	4603
lovastatin	Furosemide	14	16	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		6472	4603	6472	4603
lovastatin	Furosemide	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		6472	4603	6472	4603
lovastatin	Furosemide	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		6472	4603	6472	4603
lovastatin	Aliskiren	18	17	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		6472	325646	6472	325646
lovastatin	Aliskiren	18	17	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		6472	325646	6472	325646
lovastatin	Aliskiren	18	16	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		6472	325646	6472	325646
lovastatin	Aliskiren	18	16	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		6472	325646	6472	325646
lovastatin	Aliskiren	18	19	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		6472	325646	6472	325646
lovastatin	Aliskiren	18	19	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		6472	325646	6472	325646
lovastatin	Aliskiren	18	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		6472	325646	6472	325646
lovastatin	Aliskiren	18	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		6472	325646	6472	325646
lovastatin	Aliskiren	14	12	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		6472	325646	6472	325646
lovastatin	Aliskiren	14	12	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		6472	325646	6472	325646
lovastatin	Aliskiren	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		6472	325646	6472	325646
lovastatin	Aliskiren	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		6472	325646	6472	325646
lovastatin	Aliskiren	14	15	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		6472	325646	6472	325646
lovastatin	Aliskiren	14	15	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		6472	325646	6472	325646
lovastatin	Aliskiren	14	16	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		6472	325646	6472	325646
lovastatin	Aliskiren	14	16	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		6472	325646	6472	325646
lovastatin	hydrochlorothiazide	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		6472	5487	6472	D006852
lovastatin	hydrochlorothiazide	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		6472	5487	6472	D006852
lovastatin	hydrochlorothiazide	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		6472	5487	6472	D006852
lovastatin	hydrochlorothiazide	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		6472	5487	6472	D006852
lovastatin	Atorvastatin	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		6472	83367	6472	C065179
lovastatin	Atorvastatin	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		6472	83367	6472	C065179
celecoxib	Furosemide	18	17	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		140587	4603	C105934	4603
celecoxib	Furosemide	18	17	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		140587	4603	C105934	4603
celecoxib	Furosemide	18	16	false	none	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		140587	4603	C105934	4603
celecoxib	Furosemide	18	16	false	none	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		140587	4603	C105934	4603
celecoxib	Furosemide	14	16	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		140587	4603	C105934	4603
celecoxib	Furosemide	14	16	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		140587	4603	C105934	4603
celecoxib	Furosemide	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		140587	4603	C105934	4603
celecoxib	Furosemide	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		140587	4603	C105934	4603
celecoxib	Aliskiren	18	17	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		140587	325646	C105934	325646
celecoxib	Aliskiren	18	17	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		140587	325646	C105934	325646
celecoxib	Aliskiren	18	16	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		140587	325646	C105934	325646
celecoxib	Aliskiren	18	16	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		140587	325646	C105934	325646
celecoxib	Aliskiren	18	19	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		140587	325646	C105934	325646
celecoxib	Aliskiren	18	19	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		140587	325646	C105934	325646
celecoxib	Aliskiren	18	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		140587	325646	C105934	325646
celecoxib	Aliskiren	18	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		140587	325646	C105934	325646
celecoxib	Aliskiren	14	12	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		140587	325646	C105934	325646
celecoxib	Aliskiren	14	12	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		140587	325646	C105934	325646
celecoxib	Aliskiren	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		140587	325646	C105934	325646
celecoxib	Aliskiren	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		140587	325646	C105934	325646
celecoxib	Aliskiren	14	15	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		140587	325646	C105934	325646
celecoxib	Aliskiren	14	15	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		140587	325646	C105934	325646
celecoxib	Aliskiren	14	16	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		140587	325646	C105934	325646
celecoxib	Aliskiren	14	16	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		140587	325646	C105934	325646
celecoxib	hydrochlorothiazide	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		140587	5487	C105934	D006852
celecoxib	hydrochlorothiazide	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		140587	5487	C105934	D006852
celecoxib	hydrochlorothiazide	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		140587	5487	C105934	D006852
celecoxib	hydrochlorothiazide	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		140587	5487	C105934	D006852
celecoxib	Atorvastatin	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		140587	83367	C105934	C065179
celecoxib	Atorvastatin	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		140587	83367	C105934	C065179
Furosemide	Aliskiren	17	15	true	positive	7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  		4603	325646	4603	325646
Furosemide	Aliskiren	17	15	true	positive	7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  		4603	325646	4603	325646
Furosemide	Aliskiren	17	17	true	positive	Patients receiving furosemide could find its effect diminished after starting aliskiren.  		4603	325646	4603	325646
Furosemide	Aliskiren	17	17	true	positive	Patients receiving furosemide could find its effect diminished after starting aliskiren.  		4603	325646	4603	325646
Furosemide	Aliskiren	17	16	true	positive	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  		4603	325646	4603	325646
Furosemide	Aliskiren	17	16	true	positive	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  		4603	325646	4603	325646
Furosemide	Aliskiren	17	19	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		4603	325646	4603	325646
Furosemide	Aliskiren	17	19	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		4603	325646	4603	325646
Furosemide	Aliskiren	17	18	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	325646	4603	325646
Furosemide	Aliskiren	17	18	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	325646	4603	325646
Furosemide	Aliskiren	16	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	325646	4603	325646
Furosemide	Aliskiren	16	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	325646	4603	325646
Furosemide	Aliskiren	16	15	true	positive	7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	325646	4603	325646
Furosemide	Aliskiren	16	15	true	positive	7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	325646	4603	325646
Furosemide	Aliskiren	16	17	true	positive	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  		4603	325646	4603	325646
Furosemide	Aliskiren	16	17	true	positive	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  		4603	325646	4603	325646
Furosemide	Aliskiren	16	16	true	positive	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	325646	4603	325646
Furosemide	Aliskiren	16	16	true	positive	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	325646	4603	325646
Furosemide	Aliskiren	16	18	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	325646	4603	325646
Furosemide	Aliskiren	16	18	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	325646	4603	325646
Furosemide	Aliskiren	14	12	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		4603	325646	4603	325646
Furosemide	Aliskiren	14	12	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		4603	325646	4603	325646
Furosemide	Aliskiren	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		4603	325646	4603	325646
Furosemide	Aliskiren	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		4603	325646	4603	325646
Furosemide	Aliskiren	14	15	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		4603	325646	4603	325646
Furosemide	Aliskiren	14	15	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		4603	325646	4603	325646
Furosemide	Aliskiren	14	16	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	325646	4603	325646
Furosemide	Aliskiren	14	16	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	325646	4603	325646
Furosemide	hydrochlorothiazide	17	18	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	5487	4603	D006852
Furosemide	hydrochlorothiazide	17	18	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	5487	4603	D006852
Furosemide	hydrochlorothiazide	16	18	false	none	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	5487	4603	D006852
Furosemide	hydrochlorothiazide	16	18	false	none	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	5487	4603	D006852
Furosemide	hydrochlorothiazide	16	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	5487	4603	D006852
Furosemide	hydrochlorothiazide	16	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		4603	5487	4603	D006852
Furosemide	hydrochlorothiazide	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		4603	5487	4603	D006852
Furosemide	hydrochlorothiazide	14	14	false	none	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		4603	5487	4603	D006852
Furosemide	Atorvastatin	17	18	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	83367	4603	C065179
Furosemide	Atorvastatin	17	18	false	none	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	83367	4603	C065179
Furosemide	Atorvastatin	16	18	false	none	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	83367	4603	C065179
Furosemide	Atorvastatin	16	18	false	none	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		4603	83367	4603	C065179
cyclosporine	Aliskiren	10	8	false	none	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		3008	325646	D016572	325646
cyclosporine	Aliskiren	10	8	false	none	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		3008	325646	D016572	325646
cyclosporine	Aliskiren	10	9	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		3008	325646	D016572	325646
cyclosporine	Aliskiren	10	9	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		3008	325646	D016572	325646
cyclosporine	Aliskiren	10	10	true	positive	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		3008	325646	D016572	325646
cyclosporine	Aliskiren	10	10	true	positive	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  		3008	325646	D016572	325646
cyclosporine	Aliskiren	10	11	false	none	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  		3008	325646	D016572	325646
cyclosporine	Aliskiren	10	11	false	none	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  		3008	325646	D016572	325646
cyclosporine	Aliskiren	10	12	false	none	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		3008	325646	D016572	325646
cyclosporine	Aliskiren	10	12	false	none	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		3008	325646	D016572	325646
cyclosporine	Aliskiren	11	9	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  		3008	325646	D016572	325646
cyclosporine	Aliskiren	11	9	false	none	Concomitant use of aliskiren with itraconazole is not recommended.  Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  		3008	325646	D016572	325646
cyclosporine	Aliskiren	11	10	false	none	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  		3008	325646	D016572	325646
cyclosporine	Aliskiren	11	10	false	none	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.  Concomitant use of aliskiren with cyclosporine is not recommended.  		3008	325646	D016572	325646
cyclosporine	Aliskiren	11	11	false	none	Concomitant use of aliskiren with cyclosporine is not recommended.  		3008	325646	D016572	325646
cyclosporine	Aliskiren	11	11	false	none	Concomitant use of aliskiren with cyclosporine is not recommended.  		3008	325646	D016572	325646
cyclosporine	Aliskiren	11	12	false	none	Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		3008	325646	D016572	325646
cyclosporine	Aliskiren	11	12	false	none	Concomitant use of aliskiren with cyclosporine is not recommended.  Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  		3008	325646	D016572	325646
Aliskiren	hydrochlorothiazide	12	14	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	5487	325646	D006852
Aliskiren	hydrochlorothiazide	12	14	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	5487	325646	D006852
Aliskiren	hydrochlorothiazide	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	5487	325646	D006852
Aliskiren	hydrochlorothiazide	14	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  		325646	5487	325646	D006852
Aliskiren	hydrochlorothiazide	15	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		325646	5487	325646	D006852
Aliskiren	hydrochlorothiazide	15	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  		325646	5487	325646	D006852
Aliskiren	hydrochlorothiazide	17	18	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	5487	325646	D006852
Aliskiren	hydrochlorothiazide	17	18	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	5487	325646	D006852
Aliskiren	hydrochlorothiazide	16	18	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	5487	325646	D006852
Aliskiren	hydrochlorothiazide	16	18	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	5487	325646	D006852
Aliskiren	hydrochlorothiazide	16	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		325646	5487	325646	D006852
Aliskiren	hydrochlorothiazide	16	14	true	negative	Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.  7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  		325646	5487	325646	D006852
Aliskiren	hydrochlorothiazide	19	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		325646	5487	325646	D006852
Aliskiren	hydrochlorothiazide	19	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		325646	5487	325646	D006852
Aliskiren	hydrochlorothiazide	18	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	5487	325646	D006852
Aliskiren	hydrochlorothiazide	18	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	5487	325646	D006852
Aliskiren	Irbesartan	1	2	false	none	7  DRUG INTERACTIONS    7.1 Effects of Other Drugs on Aliskiren    Based on in vitro studies, aliskiren is metabolized by CYP 3A4.  Irbesartan: Coadministration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.  		325646	83818	325646	83818
Aliskiren	Irbesartan	1	2	false	none	7  DRUG INTERACTIONS    7.1 Effects of Other Drugs on Aliskiren    Based on in vitro studies, aliskiren is metabolized by CYP 3A4.  Irbesartan: Coadministration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.  		325646	83818	325646	83818
Aliskiren	Irbesartan	2	2	true	positive	Irbesartan: Coadministration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.  		325646	83818	325646	83818
Aliskiren	Irbesartan	2	2	true	positive	Irbesartan: Coadministration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.  		325646	83818	325646	83818
Aliskiren	Irbesartan	3	2	true	positive	Irbesartan: Coadministration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.  P-glycoprotein Effects: Pgp (MDR1/Mdr1a/1b) was found to be the major efflux system involved in absorption and disposition of aliskiren in preclinical studies.  		325646	83818	325646	83818
Aliskiren	Irbesartan	3	2	true	positive	Irbesartan: Coadministration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.  P-glycoprotein Effects: Pgp (MDR1/Mdr1a/1b) was found to be the major efflux system involved in absorption and disposition of aliskiren in preclinical studies.  		325646	83818	325646	83818
Aliskiren	Atorvastatin	3	5	false	none	P-glycoprotein Effects: Pgp (MDR1/Mdr1a/1b) was found to be the major efflux system involved in absorption and disposition of aliskiren in preclinical studies.  The potential for drug interactions at the Pgp site will likely depend on the degree of inhibition of this transporter.  Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  		325646	83367	325646	C065179
Aliskiren	Atorvastatin	3	5	false	none	P-glycoprotein Effects: Pgp (MDR1/Mdr1a/1b) was found to be the major efflux system involved in absorption and disposition of aliskiren in preclinical studies.  The potential for drug interactions at the Pgp site will likely depend on the degree of inhibition of this transporter.  Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  		325646	83367	325646	C065179
Aliskiren	Atorvastatin	5	5	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  		325646	83367	325646	C065179
Aliskiren	Atorvastatin	5	5	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  		325646	83367	325646	C065179
Aliskiren	Atorvastatin	6	5	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  		325646	83367	325646	C065179
Aliskiren	Atorvastatin	6	5	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  		325646	83367	325646	C065179
Aliskiren	Atorvastatin	7	5	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  		325646	83367	325646	C065179
Aliskiren	Atorvastatin	7	5	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  		325646	83367	325646	C065179
Aliskiren	Atorvastatin	17	18	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	83367	325646	C065179
Aliskiren	Atorvastatin	17	18	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	83367	325646	C065179
Aliskiren	Atorvastatin	16	18	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	83367	325646	C065179
Aliskiren	Atorvastatin	16	18	true	negative	Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	83367	325646	C065179
Aliskiren	Atorvastatin	19	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		325646	83367	325646	C065179
Aliskiren	Atorvastatin	19	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.  		325646	83367	325646	C065179
Aliskiren	Atorvastatin	18	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	83367	325646	C065179
Aliskiren	Atorvastatin	18	18	true	negative	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		325646	83367	325646	C065179
hydrochlorothiazide	Atorvastatin	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		5487	83367	D006852	C065179
hydrochlorothiazide	Atorvastatin	18	18	false	none	Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  		5487	83367	D006852	C065179
